Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Markers in breast cancer

D Sulitzeanu

    Israel Journal of Medical Sciences
    |September 1, 1981
    PubMed
    Summary

    Current breast cancer markers offer limited diagnostic value. Research into tumor-associated antigens (TAA) and immune complexes shows promise for improved early detection and patient monitoring.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A method for the blood-serum assay of the blood-level duration test for oily injection of procaine penicillin.

    Bulletin of the World Health Organization·2010
    Same author

    Antigen processing and presentation by EBV-carrying cell lines: cell-phenotype dependence and influence of the EBV-encoded LMP1.

    International journal of cancer·1993
    Same author

    Immunosuppressive factors in human cancer.

    Advances in cancer research·1993
    Same author

    LAK cells release a novel form of directly acting TGF beta, tightly bound to a high molecular weight carrier(s).

    Growth factors (Chur, Switzerland)·1993
    Same author

    Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population.

    Oncogene·1992
    Same author

    Degenerative changes in the A375 melanoma line induced by transforming growth factor beta 1.

    Immunology letters·1992

    Area of Science:

    • Oncology
    • Immunology
    • Biochemistry

    Background:

    • Numerous markers are evaluated for breast cancer diagnosis, prognosis, recurrence detection, and therapy response assessment.
    • Existing markers like carcinoembryonic antigen, ferritin, and haptoglobin provide limited clinical utility.
    • No single marker is specific for breast cancer, and none are elevated in all advanced cases.

    Purpose of the Study:

    • To review the current landscape of breast cancer markers.
    • To explore the potential of immune complexes and tumor-associated antigens (TAA) for improved diagnostics.
    • To identify novel markers for early detection and disease management.

    Main Methods:

    • Review of existing literature on breast cancer biomarkers.
    • Analysis of studies measuring levels of various tumor markers.
    • Investigation into the role of immune complexes and their potential as a source of TAA.

    Main Results:

    • Limited information obtained from current markers like CEA, ferritin, and haptoglobin.
    • Immune complexes found in 30-50% of patients, with potential rise in advanced disease requiring further confirmation.
    • Tumor-associated antigens (TAA) are the most promising for early diagnosis, but clinical trials are pending.
    • Analysis of immune complexes may aid in identifying breast cancer-specific TAA.

    Conclusions:

    • Current breast cancer markers have significant limitations in specificity and sensitivity.
    • Immune complex analysis holds potential for discovering novel tumor-associated antigens (TAA).
    • Further research into TAA and immune complexes is crucial for advancing breast cancer diagnostics and patient care.

    Related Experiment Videos